home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Courses and Workshops  

3rd Annual Advances in Immuno-Oncology Congress

  December 19, 2017  
Oxford Global Conferences, London

The worlds most leading authorities will give over 50 presentations across 6 interactive streams, including;

·         Discovery of Immuno-Oncology Therapies

·         Translational Immuno-Oncology

·         Genomics in Cancer Immunotherapy and Precision Medicine

·         Preclinical Development: Screening, Assays and Modelling in Immuno-Oncology

·         Immuno-Oncology Therapeutics Approaches: Clinical Research and Clinical Trials

·         Microbiome in Immuno-Oncology


Free Pre-Congress Live Webinars


Novel Checkpoint Inhibitors & Strategies for Combined Modality Treatment

Hosted by Geert Mudde, Founder and Chief Scientific Officer, TYG Oncology Ltd.

Register Here: http://bit.ly/2BeBVBc


Personalised Medicine and Immuno-Oncology

Hosted by Agnete Fredriksen, Chief Scientific Officer, Vaccibody.

Register Here: http://bit.ly/2AZUJzU



For further information, prices & discounts please contact a.fernandez@oxfordglobal.co.uk or click here: http://bit.ly/2oJlVB7

Alternatively visit our website http://bit.ly/2kiJtbg

Organized by: OxfordGlobal
Invited Speakers:

Following on from its huge success in 2017, Oxford Global are proud to present their 3rd Annual Advances in Immuno-Oncology Congress, 24-25 May, London, UK. This event will host over 300 delegates from world renowned academic institutions, hospitals, global pharmaceutical organisations and leading biotechnology companies.

Deadline for Abstracts: N/A


E-mail: a.fernandez@oxfordglobal.co.uk
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.